ONTOZRY® (cenobamate) is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic medicinal products.1
The ONTOZRY® Live Forum webinars introduced healthcare professionals across the UK to a new treatment option for adult patients with drug-resistant focal-onset seizures.
Epileptologists, Neurologists and Epilepsy Specialist Nurses joined to hear our expert panels discuss the current management of drug-resistant epilepsy as well as the latest ONTOZRY® data. The panels were led by Dr Rhys Thomas, Prof Ley Sander and Consultant Epilepsy Specialist Nurse Phil Tittensor, who each added their valued opinion on what the arrival of ONTOZRY® could mean for eligible patients.
If you were unable to attend a webinar, or want a refresh on what you heard, you can now watch the session recap videos below, which are split into three core sections.
Reference:
1. ONTOZRY® Summary of Product Characteristics.
*This event was developed and funded by Arvelle Therapeutics (part of Angelini Pharma Company) for UK Healthcare Professionals.
P-UK-CE-2100168 | December 2021
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should be reported to Arvelle Therapeutics UK on 02034889643 or at UKIReporting@angelinipharma.com.
This site is published and funded by Arvelle Therapeutics UK which is solely responsible for its content. This site is intended exclusively for UK healthcare professionals.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should be reported to Arvelle Therapeutics UK on 02034889643 or at UKIReporting@angelinipharma.com.
This site is published and funded by Arvelle Therapeutics UK which is solely responsible for its content. This site is intended exclusively for UK healthcare professionals.
Listen to leading experts discuss key evolving topics in the field of epilepsy through a focused webinar series, podcasts and more.
UK Website
Prescribing Information and Adverse Event Reporting